Update, October 31, 2026: The October 21 response deadline described below has passed. DEA’s administrative law judge later admitted the GAO report and allowed supplemental briefing but denied the request to reopen the hearing for additional discovery and testimony. The article below preserves the procedural moment as it stood on October 17; for the outcome, read DEA Judge Admits GAO Report but Refuses to Reopen Marijuana Rescheduling Hearing.
The federal rescheduling saga hit another procedural delay in mid-October, and this one had a date attached. A DEA administrative law judge gave the government until October 21 to respond to a motion to reopen the evidentiary hearing on moving the remainder of marijuana from Schedule I to Schedule III. Proceedings remained frozen while the judge considered the request.
What happened on October 14?
Chief Administrative Law Judge Derek Julius ordered the government to answer a motion from DUID Victim Voices, physician Kenneth Finn and the National Drug and Alcohol Screening Association. The groups opposed the broader Schedule III transfer and wanted the judge to admit a September GAO report, then reopen the hearing for limited discovery and testimony. At that point, the order itself did not reopen the hearing or admit the report.
What did the GAO report address?
The Government Accountability Office examined DEA and FDA controlled-substance scheduling procedures and identified documentation and procedural gaps. The later order ultimately admitted the report into the record while refusing to restart discovery. That distinction matters: a process critique is not the same thing as a finding that the scientific basis for rescheduling was invalid.
What was the October 21 deadline?
It was the deadline for the government to respond to the motion to reopen the hearing. This article was published before that deadline. The subsequent ruling admitted the GAO report, permitted supplemental briefing and denied reopening the hearing.
Why did this matter for operators?
Because the broader federal proceeding still matters economically, but the tax story is no longer as simple as “Schedule III or 280E.” In April 2026, FDA-approved marijuana products and medical marijuana products regulated under qualifying state licenses moved to Schedule III. The remainder of marijuana remains Schedule I while the broader proceeding continues.
That creates a split federal framework. Qualifying medical activity and adult-use or other marijuana activity can face different Section 280E consequences, while mixed businesses still have allocation and historical-period questions. See 280E Is No Longer One Cannabis Tax Story and Cannabis Tax Relief Promised, Guidance Missing as December 15 Nears.
What else was moving?
The April federal rule covering qualifying state-licensed medical marijuana and FDA-approved products operates separately from the proceeding over the remainder of marijuana. DEA’s own preliminary order says the medical products have already been rescheduled and are outside the scope of the broader hearing. More on the business consequences lives in the Cannabis Business and Markets collection.
Frequently Asked Questions
- What was the October 21 deadline? The date the government had to respond to a motion to reopen the broader federal marijuana-rescheduling evidentiary hearing.
- Was the hearing ultimately reopened? No. The judge later admitted the GAO report and allowed briefing but denied the request for additional discovery and testimony.
- Did medical marijuana already move to Schedule III? Qualifying state-regulated medical marijuana products and FDA-approved marijuana products did. The broader proceeding concerns the remainder of marijuana.
- Does 280E now affect every cannabis business identically? No. The 2026 split framework makes business line, licensing and tax period important to the analysis.
Primary procedural source: DEA proposed marijuana rescheduling docket. Original reporting source: IgniteIt.